Inactive Instrument

Alliance Pharma plc

APH

GB0031030819

Alliance Pharma plc Announces Termination of Mr. Peter Jonathan Butterfield as Director

Published on 01/07/2024 at 23:00

Alliance Pharma plc announced termination of Mr. Peter Jonathan Butterfield as Director. Date of termination: June 30, 2024.

Latest news about Alliance Pharma plc

Alliance Pharma Delists from London Bourse's AIM After Acquisition	05-15	MT
Aegros Bidco Completes Takeover of Alliance Pharma	05-14	MT
Alliance Pharma Says Aegros Bidco Recommends Acquisition Of Alliance Pharma	05-14	RE
Alliance Pharma plc Announces the Termination of Camillo Pane as Director, Effective May 14, 2025	05-13	CI
Alliance Pharma plc Announces the Termination of Mr. Richard Alexander Mckenzie as Director, Effective from May 14, 2025	05-13	CI
Alliance Pharma Plc Announces the Termination of Martin Sutherland as Director, Effective May 14, 2025	05-13	CI
Alliance Pharma plc Announces the Termination of Kristof Leon Neirynck as Director, Effective from May 14, 2025	05-13	CI
Alliance Pharma plc Announces the Termination of Richard Crispin Jones as Director, Effective from May 14, 2025	05-13	CI
Alliance Pharma Plc Announces the Termination of Eva-Lotta Saga Sjostedt as Director, Effective May 14, 2025	05-13	CI
An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer completed the acquisition of remaining 71.9% stake in Alliance Pharma plc from Andrew Franklin, Richard Jones, Nick Sedgwick, Slater Investments Limited and others.	05-13	CI
Aegros' Takeover of Alliance Pharma Sanctioned by Court	05-13	MT
Slater Investments Discloses 4.37% Stake In Alliance Pharma As Of 25-Apr-2025	04-29	RE
Alliance Pharma loss narrows in 2024 due to reduced impairment charges	04-08	AN
Alliance Pharma Says Group Performance In Three Months To End March In-Line With Expectations	04-08	RE
Alliance Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2024	04-08	CI
Alliance Pharma-Aegros Bidco Deal Secures Regulatory Clearances	03-21	MT
Aegros Bidco's Bid Gets Alliance Pharma Shareholders' Nod	03-13	MT
PRESS DIGEST-British Business - March 11	03-11	RE
Deals of the day-Mergers and acquisitions	03-10	RE
Alliance Pharma board backs final GBP362 million takeover bid	03-10	AN
Alliance Pharma Receives Final Increased Takeover Offer from Aegros Bidco	03-10	MT
Deals of the day-Mergers and acquisitions	03-10	RE
UK's Alliance Pharma accepts DBAY's sweetened final offer	03-10	RE
Alliance Pharma Agrees To Final Cash Offer From DBAY	03-10	RE
UK's Alliance Pharma agrees to final cash offer from asset management firm DBAY	03-10	RE

Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.

Employees

290

Sector

Pharmaceuticals

More about the company